Santaris Pharma A/S, a privately held clinical-stage biopharmaceutical company, is focused on the discovery and development of RNA-targeted therapies using its proprietary LNA Drug Platform
events
Santaris Pharma A/S was named by FierceBiotech as one of 2008's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.